NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
17 patients with chronic lymphocytic leukemia (CLL) in remission at a median of 15.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
We performed next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in 17 patients with chronic lymphocytic leukemia (CLL) in remission at a median of 15.7 years post fludarabine, cyclophosphamide, and rituximab (FCR) and identified persistent MRD in 13/17 (76%) patients.
OpenAlex 토픽 ·
Chronic Lymphocytic Leukemia Research
Immunodeficiency and Autoimmune Disorders
Lymphoma Diagnosis and Treatment
We performed next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in 17 patients with chronic lymphocytic leukemia (CLL) in remission at a median of 15.7 years post flud
APA
Alexandre Bazinet, Alessandra Ferrajoli, et al. (2026). NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020243
MLA
Alexandre Bazinet, et al.. "NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.." Blood advances, 2026.
PMID
41879712 ↗
Abstract 한글 요약
We performed next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in 17 patients with chronic lymphocytic leukemia (CLL) in remission at a median of 15.7 years post fludarabine, cyclophosphamide, and rituximab (FCR) and identified persistent MRD in 13/17 (76%) patients.